Dasotraline showed significant improvement in efficacy compared to placebo at week 1 and throughout the study for children aged 6 to 12 years with attention deficit hyperactivity disorder (ADHD) which could be a promising new treatment.
A detailed description of the trial design and the results is published in the Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Advertisement
‘Dasotraline could benefit children with ADHD aged 6-12 more compared to placebo.’
Tweet it Now
Robert Goldman, PhD, Sunovion Pharmaceuticals (Marlborough, MA and Fort Lee, NJ), and colleagues from Kennedy Krieger Institute/Johns Hopkins University (Baltimore, MD), New York University Langone Medical Center (New York, NY), and Massachusetts General Hospital (Boston, MA) coauthored the article entitled "Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial."
The researchers conducted a 6-week trial in which children with a diagnosis of ADHD received a once-daily morning dose of dasotraline (2mg or 4mg) or placebo. The primary endpoint to determine efficacy was an ADHD rating scale that determined change from baseline. Treatment with dasotraline 4g/day only was associated with significant improvement in efficacy.
Dasotraline also showed significant improvement for some secondary efficacy endpoints, including measures of hyperactivity and inattentiveness. The study also assessed the safety of dasotraline treatment and performed subgroup analysis to look for differences in safety and efficacy across subgroups such as age, gender, and use of other treatments for ADHD.
"Over four million children suffer from ADHD. The investigation of new, safe treatments with less side effects is needed for this patient group," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
Source: Eurekalert
Advertisement
Dasotraline also showed significant improvement for some secondary efficacy endpoints, including measures of hyperactivity and inattentiveness. The study also assessed the safety of dasotraline treatment and performed subgroup analysis to look for differences in safety and efficacy across subgroups such as age, gender, and use of other treatments for ADHD.
"Over four million children suffer from ADHD. The investigation of new, safe treatments with less side effects is needed for this patient group," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Child Health News
The presence of Streptococcus in the placenta was associated with a two- to three-fold increase in the probability of neonatal unit admission.
Facing discrimination and acculturating during pregnancy could not only affect the mother but also potentially harm the baby's brain health.
A number of pathogens are to blame for the rise in childhood acute respiratory diseases, according to Chinese health officials.
World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC) highlight the deficiencies in disease surveillance efforts.
Need for gender-specific interventions in brain injuries has been highlighted by a new study due to its higher prevalence in newborn boys.